Objectives: An accurate pre-operative diagnosis of an adnexal mass is important to make patient management decisions. IOTA models (LR2, the Simple Rules risk scoring system SRrisks, ADNEX) discriminate well between benign and malignant masses, but this is not sufficient to guarantee clinical utility. Here, we evaluate the clinical utility of RMI, ROMA, LR2, ADNEX, and the SRrisks for referring patients to specialised oncology care.
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Methods:
We performed a secondary analysis of data from two cross-sectional cohort studies. Data was available on 2763 patients (2403 in dataset 1 and 360 in dataset 2) from 18 centres (11 oncology centres and 7 non-oncology hospitals) in 6 countries. Excised tissue was histologically classified as benign or malignant. The clinical utility of the pre-operative diagnostic models was assessed with Net Benefit (NB) at a range of sensible risk thresholds (5% to 50% risk of malignancy) to refer patients to specialised oncology care. NB accounts for the different harm of missing a malignancy versus unnecessary treatment of a benign tumour. Results: The prevalence of malignancy was 41% in dataset 1 and 40% in dataset 2. For risk thresholds up to 10-15%, RMI and ROMA had less utility than simply referring all patients to specialised oncology care. SRRisks and ADNEX had the highest NB. At a risk threshold of 20%, the NBs of ADNEX, SRrisks and RMI were 0.348, 0.350, and 0.270, respectively. Results by menopausal status and type of centre (oncology versus non-oncology) were similar.
Conclusions:
The results indicate that ADNEX and the SRrisks are the best models to decide which patients to refer to specialised oncology care. This should ultimately lead to improved patient survival, decreased morbidity and reduced healthcare expenditures.
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